FierceBiotech names Jnana Therapeutics as one of its “Fierce 15” Biotech Companies of 2018
Boston, Mass. – October 2, 2018 – Jnana Therapeutics today announced that it has been named by FierceBiotech as one of 2018’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
Jnana Therapeutics was launched in 2017 to build the first drug discovery platform targeting the solute carrier (SLC) family of metabolite transporters, which are the gates used by the cell to control metabolite movement. The company is taking a comprehensive approach to understanding SLCs and their underlying biology in order to unlock a new wave of druggable targets. From there, they are discovering and developing medicines to modulate critical disease pathways to improve outcomes for patients with severe diseases.
“We are pleased to be recognized as a Fierce 15 company, an award which reflects the innovative nature of our drug discovery platform and its potential to unlock SLC transporters as a novel therapeutic target class,” said Joanne Kotz, Ph.D., Cofounder and President at Jnana. “Our purpose at Jnana is to push the frontiers of scientific knowledge by pioneering the comprehensive understanding and targeting of the SLC transporter family, which has never been systematically addressed in drug development, and create a new class of medicines that make a positive impact on patients and their families.”
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s 16th annual Fierce 15 selection.
An internationally recognized daily report reaching a network of over 285,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
FierceBiotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Signup is free at www.fiercebiotech.com/signup.
About Jnana Therapeutics
Jnana Therapeutics is a biotechnology company creating the first drug discovery platform to unlock the solute carrier (SLC) family of metabolite transporters as a therapeutic target class. Jnana is systematically targeting SLCs, the cell’s metabolic gates, to advance first-in-class therapies for diseases where patients have limited or no treatment options. Headquartered in Boston, Jnana launched in 2017 with $50 million in Series A financing from investors including Polaris Partners, Avalon Ventures, Versant Ventures, AbbVie Ventures and Pfizer R&D Innovate. For more information, please visit www.jnanatx.com, and follow us on Twitter and on LinkedIn.
Ten Bridge Communications